CHARLESTON, S.C., March 19, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) will
announce its fourth quarter and year ended December 31, 2018 financial and operating results after market close on Tuesday, March
26, 2019.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on commercializing novel pharmaceutical therapies,
principally through out-licensing arrangements. Aeterna Zentaris is a party to a license and assignment agreement with a subsidiary
of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the
United States and Canada. For more information, visit www.zentaris.com.
Forward-Looking Statements
This press release contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the
safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future
events. Forward-looking statements may include, but are not limited to statements preceded by, followed by, or that include
the words "will," "expects," "believes," "intends," "would," "could," "may," "anticipates," and similar terms that relate to future
events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties, including those
discussed in this press release and in our Annual Report on Form 20-F, under the caption "Key Information - Risk Factors" filed
with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and
Exchange Commission. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in
forward-looking statements. Such risks and uncertainties include, among others, our now heavy dependence on the success of
Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to
successfully launch the product, our strategic review process, the ability of the Special Committee to carry out its mandate, the
ability of Aeterna Zentaris to enter into out-licensing, development, manufacturing and marketing and distribution agreements with
other pharmaceutical companies and keep such agreements in effect, reliance on third parties for the manufacturing and
commercialization of our product candidates, potential disputes with third parties, leading to delays in or termination of the
manufacturing, development, out-licensing or commercialization of our product candidates, or resulting in significant litigation or
arbitration, and, more generally, uncertainties related to the regulatory process, our ability to efficiently commercialize or
out-license Macrilen™ (macimorelin), the degree of market acceptance of Macrilen™ (macimorelin), our ability to obtain necessary
approvals from the relevant regulatory authorities to enable us to use the desired brand names for our products, the impact of
securities class action litigation or other litigation on our cash flow, results of operations and financial position, our ability
to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, the
potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult our
quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and
uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these
forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of
the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a
governmental authority or applicable law.
Contacts:
Aeterna Zentaris Inc.
Leslie Auld
Chief Financial Officer
IR@aezsinc.com
843-900-3211